<tt id="6hsgl"><pre id="6hsgl"><pre id="6hsgl"></pre></pre></tt>
          <nav id="6hsgl"><th id="6hsgl"></th></nav>
          国产免费网站看v片元遮挡,一亚洲一区二区中文字幕,波多野结衣一区二区免费视频,天天色综网,久久综合给合久久狠狠狠,男人的天堂av一二三区,午夜福利看片在线观看,亚洲中文字幕在线无码一区二区
          您現在的位置: > Language Tips > Audio & Video > Special Speed News  
           





            Once-daily pill could simplify HIV treatment
          [ 2006-02-06 15:57 ]


          I’m Steve Ember with the VOA Special English Health Report.


          Myers Squibb and Gilead Sciences have combined many H.I.V. drugs into a single pill
          Sometimes the best medicine is more than one kind of medicine. Malaria, tuberculosis and H.I.V./AIDS, for example, are all treated with combinations of drugs.

          But that can mean a lot of pills to take. It would be simpler if drug companies combined all the medicines into a single pill, taken just once a day.

          Now, two companies say they have done that for people just starting treatment for H.I.V., the virus that causes AIDS. The companies are Bristol-Myers Squibb and Gilead Sciences.

          They have developed a single pill that combines three drugs currently on the market. Bristol-Myers Squibb sells one of them under the name Sustiva. Gilead combined the others, Emtriva and Viread, into a single pill in two thousand four.

          Combining drugs involves more than technical issues. It also involves issues of competition if the drugs are made by different companies. The new once-daily pill is the result of what is described as the first joint venture agreement of its kind in the treatment of H.I.V.

          In January the New England Journal of Medicine published a study of the new pill. Researchers compared its effectiveness to that of the widely used combination of Sustiva and Combivir. Combivir contains two drugs, AZT and 3TC. The researchers say that after one year of treatment, the new pill suppressed H.I.V. levels in more patients and with fewer side effects.

          Gilead paid for the study. Professor Joel Gallant at the Johns Hopkins School of Medicine in Baltimore, Maryland, led the research. He is a paid adviser to Gilead and Bristol-Meyers Squibb as well as the maker of Combivir, GlaxoSmithKline.

          GlaxoSmithKline reacted to the findings by saying that a single study is of limited value. It says the effectiveness of Combivir has been shown in each of more than fifty studies.

          The price of the new once-daily pill has not been announced. But Gilead and Bristol-Myers Squibb say they will provide it at reduced cost to developing countries.

          They plan in the next few months to ask the United States Food and Drug Administration to approve the new pill.

          There are limits to who could take it because of the different drugs it contains. For example, pregnant women are told not to take Sustiva because of the risk of birth disorders.

          Experts say more than forty million people around the world are living with H.I.V.

          This VOA Special English Health Report was written by Cynthia Kirk. Read and listen to our reports at voaspecialenglish.com. I’m Steve Ember.

          Vocabulary

           

           

           
           
           




          主站蜘蛛池模板: 国产免费无遮挡吸乳视频在线观看| 欧美日本激情| 日本特黄特黄aaaaa大片| 亚洲国产日韩一区三区| 国产美女免费永久无遮挡| 亚洲性一交一乱一伦视频| 久久精品女人的天堂av| 亚洲欧洲∨国产一区二区三区| 亚洲AV无码精品色午夜果冻| 国内a级毛片| 亚洲精品一区二区区别| 国产深夜福利在线免费观看| 日韩精品一卡二卡三卡在线 | 男女肉粗暴进入120秒视频| 精品黄色av一区二区三区| 波多野结衣久久一区二区| 尤物国精品午夜福利视频| 国产妇女馒头高清泬20p多毛| 国产精品久久欧美久久一区| 麻花传剧mv在线看免费| 无码午夜人妻一区二区三区不卡视频| 中文字幕国产原创国产| 国产精品盗摄!偷窥盗摄| 高清偷拍一区二区三区| 免费观看又色又爽又黄的韩国| 精品精品久久宅男的天堂| 97久久久亚洲综合久久| 国产精品国产三级国av| 人妻无码av中文系列久| 亚洲中文一区二区av| 久久精品国产99久久丝袜| 欧美性69式xxxx护士| 国产偷国产偷亚洲清高APP| 色妺妺视频网| 国产成人A在线视频免费| 另类欧美日韩| 久久精品免视看国产成人| 国产免费又色又爽又黄软件| 老色批国产在线观看精品| 野外做受又硬又粗又大视频| 国产成人精品一区二区三区 |